At close: September 27 at 4:00 PM EDT
After hours: September 27 at 6:24 PM EDT
Research Analysis
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 10 | 9 | 10 | 9 |
| Avg. Estimate | 0.21 | -0.75 | -2 | -2.55 |
| Low Estimate | -0.89 | -1.02 | -3.54 | -4.05 |
| High Estimate | 0.81 | 0.2 | -0.36 | -1.42 |
| Year Ago EPS | 0.28 | -0.75 | -0.15 | -2 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 7 | 8 | 8 | 7 |
| Avg. Estimate | 76.11M | 22.48M | 121.29M | 87.71M |
| Low Estimate | 12.3M | 7.7M | 44.6M | 47.3M |
| High Estimate | 111.47M | 91.3M | 186M | 138.77M |
| Year Ago Sales | 10.4M | 10.72M | 58.75M | 121.29M |
| Sales Growth (year/est) | 632.00% | 109.70% | 106.50% | -27.70% |
Earnings History
| CURRENCY IN USD | 9/30/2023 | 12/31/2023 | 3/31/2024 | 6/30/2024 |
|---|---|---|---|---|
| EPS Est. | -0.1 | -0.15 | -0.64 | -0.59 |
| EPS Actual | 0.28 | -0.75 | -0.84 | -0.89 |
| Difference | 0.38 | -0.6 | -0.2 | -0.3 |
| Surprise % | 380.00% | -400.00% | -31.20% | -50.80% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0.21 | -0.75 | -2 | -2.55 |
| 7 Days Ago | 0.21 | -0.75 | -2 | -2.55 |
| 30 Days Ago | 0.26 | -0.75 | -2.19 | -2.55 |
| 60 Days Ago | -0.76 | -0.62 | -2.83 | -2.01 |
| 90 Days Ago | -0.76 | -0.62 | -2.83 | -2.05 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | MGNX | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -25.00% | -- | -- | 5.60% |
| Next Qtr. | 0.00% | -- | -- | 9.90% |
| Current Year | -1,233.30% | -- | -- | 3.40% |
| Next Year | -27.50% | -- | -- | 12.70% |
| Next 5 Years (per annum) | -283.60% | -- | -- | 11.90% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Neutral to Neutral | 9/18/2024 |
| Reiterates | HC Wainwright & Co.: Neutral to Neutral | 8/21/2024 |
| Maintains | Citigroup: Buy to Buy | 8/15/2024 |
| Maintains | BMO Capital: Market Perform to Market Perform | 8/7/2024 |
| Downgrade | BTIG: Buy to Neutral | 8/1/2024 |
| Reiterates | HC Wainwright & Co.: Neutral to Neutral | 8/1/2024 |
Related Tickers
KPTI Karyopharm Therapeutics Inc.
0.7239
+2.46%
MRSN Mersana Therapeutics, Inc.
1.8500
0.00%
CTMX CytomX Therapeutics, Inc.
1.2000
0.00%
ALXO ALX Oncology Holdings Inc.
1.9700
+5.35%
XNCR Xencor, Inc.
20.25
-1.03%
SAGE Sage Therapeutics, Inc.
7.29
+1.67%
MRNS Marinus Pharmaceuticals, Inc.
1.8400
+6.36%
ZNTL Zentalis Pharmaceuticals, Inc.
3.7500
+1.63%
AGEN Agenus Inc.
5.31
+2.71%
VTYX Ventyx Biosciences, Inc.
2.3100
-2.12%